Stockscreener 앱 받기
2.12
11.67%
-0.28
시간 외 거래:
2.29
0.17
+8.02%
전일 마감가:
$2.40
열려 있는:
$2.46
하루 거래량:
159.85K
Relative Volume:
1.06
시가총액:
$79.73M
수익:
-
순이익/손실:
$-13.27M
주가수익비율:
-12.93
EPS:
-0.164
순현금흐름:
$-7.70M
1주 성능:
+9.28%
1개월 성능:
+10.99%
6개월 성능:
-23.74%
1년 성능:
+89.29%
1일 변동 폭
$2.10
$2.4817
1주일 범위
$1.94
$2.4817
52주 변동 폭
$0.9016
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
OKYO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.12 | 90.27M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 개시 | B. Riley Securities | Buy |
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target - Investing.com
OKYO Pharma appoints Robert Dempsey as new CEO By Investing.com - Investing.com Nigeria
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential - TipRanks
OKYO Pharma appoints Ophthalmology veteran Robert Dempsey as new CEO - Proactive financial news
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO - Proactive financial news
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer - BioSpace
OKYO Pharma names Robert J. Dempsey as chief executive officer By Investing.com - Investing.com Australia
OKYO Pharma names Robert J. Dempsey as chief executive officer - Investing.com
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase - TipRanks
Is Alico Inc stock a smart buy before Fed meetingRisk Management & Fast Exit and Entry Trade Guides - moha.gov.vn
Will OKYO Pharma Limited stock remain a Wall Street favoriteTrendline Breakouts & Free High Yield Portfolio Picks - bollywoodhelpline.com
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target By Investing.com - Investing.com India
Technical Analysis: What dividend safety score for OKYO Pharma Limited stockMarket Activity Recap & Fast Moving Stock Trade Plans - moha.gov.vn
OKYO Pharma reports positive phase 2 results for Urcosimod in neuropathic corneal pain - MSN
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
Will OKYO Pharma Limited stock maintain dividend yieldJuly 2025 Catalysts & Trade Opportunity Analysis Reports - Улправда
Volatility Watch: How OKYO Pharma Limited OK11 stock gains from tech spendingJuly 2025 Price Swings & Verified High Yield Trade Plans - moha.gov.vn
Bank Watch: What Wall Street predicts for OKYO Pharma Limited stock priceJuly 2025 Levels & Daily Chart Pattern Signals - Улправда
Will OKYO Pharma Limited (OK11) stock hit analyst forecastsMarket Trend Review & Weekly High Return Stock Opportunities - Улправда
Is OKYO Pharma Limited stock affected by interest rate hikesTake Profit & AI Powered Market Trend Analysis - Улправда
Will OKYO Pharma Limited stock see PE expansionJuly 2025 Reactions & Stock Market Timing Techniques - Улправда
Small cap wrap: Gunnison Copper, OKYO Pharma, Abacus Global Management… - Proactive Investors
Is OKYO Pharma Limited (OK11) stock suitable for passive index fundsJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - Улправда
OKYO Pharma management to ring Nasdaq opening bell in New York - Investing.com Australia
Pullback Watch: Why retail investors pile into OKYO Pharma Limited stock2025 Market WrapUp & AI Driven Stock Movement Reports - DonanımHaber
OKYO Pharma Ltd Rings the Nasdaq Stock Market Opening Bell - Nasdaq
OKYO Pharma Ltd Rings the Opening Bell - Nasdaq
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors
OKYO Pharma management to ring Nasdaq opening bell in New York By Investing.com - Investing.com South Africa
OKYO Pharma Rings Nasdaq Opening Bell as Urcosimod Advances After Positive Phase 2 NCP Data - TipRanks
Will OKYO Pharma Limited stock outperform growth indexesPortfolio Risk Report & High Conviction Trade Alerts - DonanımHaber
OKYO Pharma to Ring the Opening Bell at Nasdaq - The Manila Times
How OKYO Pharma Limited (OK11) stock gains from tech spendingMarket Performance Summary & Expert Verified Stock Movement Alerts - DonanımHaber
Why OKYO Pharma Limited stock is rated strong buy2025 Growth vs Value & Comprehensive Market Scan Insights - DonanımHaber
Is OKYO Pharma Limited stock trading at a premium valuationPortfolio Risk Summary & Detailed Earnings Play Alerts - Улправда
Will OKYO Pharma Limited stock deliver long term returnsBreakout Watch & High Conviction Investment Ideas - Улправда
Is OKYO Pharma Limited stock positioned for digital transformation2025 Retail Activity & Precise Swing Trade Alerts - Улправда
OKYO Pharma reports favorable phase 2 data for NCP asset - Eyes On Eyecare
Okyo Pharma executive chairman increases stake in company By Investing.com - Investing.com Australia
Okyo Pharma executive chairman increases stake in company - Investing.com India
Okyo Pharma chairman acquires 24,551 company shares - TipRanks
Panetta Partners increases stake in OKYO Pharma with new share purchase - Investing.com Canada
Check out OKYO Pharma Ltd's stock price (OKYO) in real time - CNBC
Panetta Partners increases stake in OKYO Pharma with new share purchase By Investing.com - Investing.com South Africa
OKYO Pharma Chairman Increases Stake Amid Promising Drug Trials - TipRanks
OKYO Pharma Announces Chairman and Founder Acquires Shares - The Manila Times
Okyo Pharma Limited (OKYO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):